SanBio Company (SNBIF) Fair Value & Analysis
Healthcare · US · Market cap $1.3B
SanBio Company
SNBIF · US
Fair value as of: Jul 19, 2026
From 1 valuation models · updated yesterday
Fair value updated Jul 19, 2026, revised from $0.6300 to $42.61 (+6,663.5%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $6.55 – $16.45 · fair‑value band $28.12 – $53.26 · the $16.45 price screens below the $42.61 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SanBio Company (SNBIF) currently trades at $16.45, while our model-based Fair Value estimate is $42.61, implying the stock looks roughly 159.0% undervalued today. We read business quality at 47/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Revenue declined 86.7% year over year. It earns a return on equity of -43.2%. Fundamentals as of Jul 19, 2026
Our scenario range runs from $28.12 (bear case) to $53.26 (bull case); at $16.45, the current price sits below that range. The share trades near its 52-week high and 327% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at 159%, SNBIF screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SanBio Company reported revenue of $0 in FY2025 versus $22.9M in FY2021. Reported net income was −$2.9B in FY2025.
Is SNBIF fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $935.38 | $382.64 | -59% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$112.04 | A$106.56 | -5% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SanBio Company (SNBIF) undervalued?
What is the fair value of SNBIF?
What is the quality score of SNBIF?
What is the net profit margin of SNBIF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full SanBio Company analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.